The following information is being provided to TPA members at the request of BlueCross BlueShield of Tennessee (BCBST). Note that the change referenced applies only to Medicare Part D plans administered by BCBST.
Medicare Part D Formulary Change
Effective January 1, 2014, Lilly Humalog and Humulin will be the preferred insulin status for Medicare Part D formularies. Novo Nordisk Novolog and Novolin will be non-formulary and no longer covered by the Part D Plan Sponsors.
All Covered Persons were notified of this formulary change via their Plan Annual Notice of Change letter. In addition, Covered Persons utilizing Novo Nordisk insulin and their Prescribing Providers were sent a notification regarding the change in formulary.
To ensure a smooth transition for impacted Covered Persons, Participating Pharmacies are encouraged to assist their Covered Persons to get a new prescription from their Prescribing Provider prior to January 1, 2014.
Please note: If Covered Persons are switching to the Value formulary, the Basal insulin on formulary is Lantus.